Browse by Audience
Skip to content
Papers of the Week
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.
Abstract
Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with prior preventive treatment failures benefit more from the 140 mg dose than the 70 mg.